METTL3 and neoplasm: As shown in Table 3, univariate analysis showed that in addition to lymph node involvement and clinical stage, high levels of METTL3 in tumour cells (HR: 4.244, P = 0.002) and in tumour-infiltrating immune cells (HR: 4.857, P = 0.004) and a high density of CD33+ MDSCs (HR: 6.579, P = 0.002) were noticeably correlated with reduced DFS.